Chairman and Chief Executive Officer of Eli Lilly & Co., John Lechleiter returned to his positions full-time after undergoing a heart surgery to fix a heart defect in May.

The May 13 surgery was intended to repair a dilated aorta. The condition arises when the arteries that carry blood from the heart through the chest swell, according to the National Institutes of Health. The company had previously said that Lechleiter's condition was found during an unrelated test.

Indianapolis-based Lilly said in a statement that the procedure was successful and the recovery was timely. Both the company physician and Lechleiter's personal doctor cleared him for work. Chief Financial Officer Derica Rice, acting CEO while Lechleiter was on medical leave, will continue as CFO. 

Lechleiter said in a statement, "I return to Lilly with renewed energy and enthusiasm, along with a new perspective on health and wellness and the critical importance of new medicines in advancing patient care."

Lilly shares increased 1.1 % to $51.13 on Monday in New York. The value have risen up to 20% in the past 12 months.